Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Forte Biosciences, Inc. (NASDAQ: FBRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Forte is a clinical-stage biopharmaceutical company focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases, and its filings document key financial, clinical and corporate developments around this program.
Through forms such as 10-Q and 8-K, Forte reports its quarterly financial results, including research and development expenses tied to FB102 clinical and manufacturing activities, general and administrative costs, and net loss figures. Current reports on Form 8-K also disclose material events such as positive phase 1b data in celiac disease, the initiation and status of clinical trials, and the filing of related investor presentations.
Forte’s filings further describe capital markets transactions, including an underwriting agreement for a public offering of common stock and pre-funded warrants. In these documents, the company outlines the number of shares and pre-funded warrants offered, expected gross and net proceeds, use of proceeds for working capital and FB102 development, and the terms and limitations associated with the pre-funded warrants.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points from lengthy documents, helping readers quickly understand the implications of Forte’s 10-Qs, 8-Ks and other filings. Real-time updates from the EDGAR system, along with organized access to financial reports and material event disclosures, allow investors and researchers to review Forte Biosciences’ regulatory history and ongoing obligations as a Nasdaq-listed, clinical-stage biopharmaceutical company.
Janus Henderson Group plc has disclosed a significant ownership position in Forte Biosciences, Inc. Through its investment adviser subsidiaries, it may be deemed to beneficially own 1,425,785 shares of Forte common stock, representing 11.4% of the outstanding class as of the reporting date.
The shares are held in various managed portfolios for clients, with the asset managers sharing voting and dispositive power over all 1,425,785 shares and having no sole power. The filing also notes 521,016 pre-funded warrants held in managed portfolios that cannot be exercised if doing so would push ownership above 9.99% of Forte. Dividends and sale proceeds belong to the underlying client accounts, not Janus Henderson.
Affinity Asset Advisors, LLC and Michael Cho filed an amended Schedule 13G reporting their beneficial ownership in Forte Biosciences. They beneficially own 834,964 shares of common stock, including listed call options exercisable for 22,400 shares, representing about 6.7% of the company.
The filing notes that as of December 31, 2025, they beneficially owned approximately 8.1% of Forte Biosciences, so their ownership percentage has decreased. They certify that the position is held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the company.
Forte Biosciences, Inc. reported a new large shareholder disclosure. Investment entities affiliated with Point72, including Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, filed a Schedule 13G reporting beneficial ownership of 792,976 shares of Forte Biosciences common stock, representing 6.3% of the outstanding class as of the close of business on January 16, 2026.
The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, with shared voting and dispositive power over all 792,976 shares and no sole voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Forte Biosciences.
Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, received new equity awards effective January 12, 2026. The awards include a stock option covering 90,000 shares of common stock with an exercise price of $29.66 per share and an expiration date of January 12, 2036, and a grant of 60,000 restricted stock units (RSUs).
The option vests monthly, with one forty-eighth of the total option shares vesting each month starting from a vesting commencement date of January 1, 2026, so that the option is fully vested after four years. The RSUs vest annually, with one fourth of the total RSUs vesting on each anniversary of the same January 1, 2026 vesting commencement date, resulting in full vesting over four years, assuming the CFO continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported new equity awards to a senior executive. A Form 4 filing shows that on January 12, 2026, CEO, Secretary and Chair Paul A. Wagner received a stock option covering 270,000 shares of Forte Biosciences common stock with an exercise price of $29.66 per share. According to the vesting terms, one forty-eighth of the option vests each month after a vesting commencement date of January 1, 2026, so the option becomes fully vested after four years, as long as he continues as a service provider.
The filing also reports a grant of 180,000 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock. These RSUs vest in four equal annual installments on each anniversary of the same January 1, 2026 vesting commencement date, again conditioned on continued service. Following these grants, Wagner beneficially owns 270,000 stock options and 180,000 RSUs directly.
Forte Biosciences, Inc. received an updated ownership report from investor Steven Michael Oliveira and Nemean Asset Management, LLC. Together they report beneficial ownership of 300,100 shares of Forte Biosciences common stock, representing 2.4% of the outstanding class as of the event date of 01/08/2026. Voting and disposition power over these shares is reported as shared rather than sole.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Forte Biosciences, and that they are not participating in any control-related transaction.
Forte Biosciences (FBRX) filed its Q3 2025 10‑Q, reporting continued investment in FB102 and a larger cash position. The company recorded a Q3 net loss of
Cash and cash equivalents were
FB102 advanced clinically: a Phase 2 celiac study began in July 2025, and the FDA approved an IND in November 2025 for a U.S. arm. Earlier, the celiac Phase 1b showed statistically significant histology and symptom improvements. Vitiligo and alopecia areata Phase 1b studies are ongoing. Shares outstanding were 12,526,935 as of November 7, 2025; 5,304,511 pre‑funded warrants remained outstanding as of quarter‑end.
Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is included as Exhibit 99.1 to the report.
Federated Hermes, Inc. and affiliated reporting persons disclosed beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock, representing 13.15% of the class as of the event date. The filing lists Federated Hermes, Inc. (a Pennsylvania entity) and the Voting Shares Irrevocable Trust as holders with sole voting and dispositive power over the 1,635,380 shares, while three individuals — Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue — are reported with shared voting and dispositive power over the same aggregate amount.
The statement affirms the securities were acquired and are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The filing includes exhibits for classification of reporting persons, a joint filing agreement, and a power of attorney.
Forte Biosciences insider Riley Antony A, identified as the company's Chief Financial Officer, reported transactions dated 10/01/2025. The filing shows 375 restricted stock units (RSUs) were recorded as acquired/awarded with a $0 per-share conversion value, representing a contingent right to receive one share each. The report also discloses a separate sale/disposition of 134 common shares at $14.52 per share. Following the transactions, the filing lists 31,974 and 31,840 shares beneficially owned in the non-derivative lines and 1,875 shares underlying RSUs in the derivative section. The RSU award vests quarterly at one-sixteenth per quarter, subject to continued service, per the 2021 Equity Incentive Plan.